These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36517423)

  • 21. [Initial experience with detection of Saccharomyces cerevisiae antibodies in patients with primary nonspecific inflammatory bowel disease].
    Malícková K; Janatková I; Fucíková T; Adamec S; Lukás M
    Epidemiol Mikrobiol Imunol; 2001 Aug; 50(3):131-5. PubMed ID: 11550421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Significance of serum antibodies ANCA, ASCA, ABBA in diagnostics of idiopathic intestinal inflammations].
    Pintér M; Pintérová KM; Drahosová M; Rejchrt S; Douda T; Tachecí I; Kopácová M; Bures J
    Cas Lek Cesk; 2007; 146(11):863-7. PubMed ID: 18069213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
    Bansi DS; Chapman RW; Fleming KA
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives.
    Demirsoy H; Ozdil K; Ersoy O; Kesici B; Karaca C; Alkim C; Akbayir N; Erdem LK; Onuk MD; Beyzadeoglu HT
    World J Gastroenterol; 2010 Dec; 16(45):5732-8. PubMed ID: 21128324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Proteinase 3 Antibodies as a Biomarker for Ulcerative Colitis and Primary Sclerosing Cholangitis in Children.
    Laass MW; Ziesmann J; de Laffolie J; Röber N; Conrad K
    J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):463-470. PubMed ID: 35703948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role.
    Quinton JF; Sendid B; Reumaux D; Duthilleul P; Cortot A; Grandbastien B; Charrier G; Targan SR; Colombel JF; Poulain D
    Gut; 1998 Jun; 42(6):788-91. PubMed ID: 9691915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.
    Sandborn WJ; Loftus EV; Colombel JF; Fleming KA; Seibold F; Homburger HA; Sendid B; Chapman RW; Tremaine WJ; Kaul DK; Wallace J; Harmsen WS; Zinsmeister AR; Targan SR
    Inflamm Bowel Dis; 2001 Aug; 7(3):192-201. PubMed ID: 11515844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China.
    Zhou F; Xia B; Wang F; Shrestha UK; Chen M; Wang H; Shi X; Chen Z; Li J
    Clin Chim Acta; 2010 Oct; 411(19-20):1461-5. PubMed ID: 20570669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic role of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in pediatric inflammatory bowel disease].
    Kim JE; Kim KS; Seo JK
    Korean J Gastroenterol; 2003 Oct; 42(4):297-302. PubMed ID: 14634349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis.
    Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP
    J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.
    Takaishi H; Kanai T; Nakazawa A; Sugata F; Nikai A; Yoshizawa S; Hamamoto Y; Funakoshi S; Yajima T; Iwao Y; Takemura M; Ozaki S; Hibi T
    J Gastroenterol; 2012 Sep; 47(9):969-77. PubMed ID: 22644337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients.
    Lawrance IC; Murray K; Hall A; Sung JJ; Leong R
    Am J Gastroenterol; 2004 Nov; 99(11):2186-94. PubMed ID: 15555001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody in Iranian patients with inflammatory bowel disease.
    Bahari A; Aarabi M; Aarabi M; Hedayati M; Jarollahi A; Firouzi F; Aghazadeh R; Zali MR; Hashemi M
    Acta Gastroenterol Belg; 2009; 72(3):301-5. PubMed ID: 19902862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
    Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Saccharomyces cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies are not increased in Takayasu arteritis.
    Ozbakir F; Ugurlu S; Celik AF; Seyahi E
    Acta Reumatol Port; 2011; 36(1):20-3. PubMed ID: 21483276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serological markers predict inflammatory bowel disease years before the diagnosis.
    van Schaik FD; Oldenburg B; Hart AR; Siersema PD; Lindgren S; Grip O; Teucher B; Kaaks R; Bergmann MM; Boeing H; Carbonnel F; Jantchou P; Boutron-Ruault MC; Tjønneland A; Olsen A; Crowe FL; Peeters PH; van Oijen MG; Bueno-de-Mesquita HB
    Gut; 2013 May; 62(5):683-8. PubMed ID: 22842615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenotypic associations of Crohn's disease with antibodies to flagellins A4-Fla2 and Fla-X, ASCA, p-ANCA, PAB, and NOD2 mutations in a Swiss Cohort.
    Schoepfer AM; Schaffer T; Mueller S; Flogerzi B; Vassella E; Seibold-Schmid B; Seibold F
    Inflamm Bowel Dis; 2009 Sep; 15(9):1358-67. PubMed ID: 19253375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serological markers facilitate the diagnosis of Crohn's disease.
    Gao X; Zhang Y
    Postgrad Med; 2021 Apr; 133(3):286-290. PubMed ID: 33406965
    [No Abstract]   [Full Text] [Related]  

  • 39. Combining TNFSF15 and ASCA IgA can be used as a predictor for the stenosis/perforating phenotype of Crohn's disease.
    Tung CC; Wong JM; Lee WC; Liu HH; Chang CH; Chang MC; Chang YT; Shieh MJ; Wang CY; Wei SC
    J Gastroenterol Hepatol; 2014 Apr; 29(4):723-9. PubMed ID: 24783249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of antibodies anti-saccharomyces cerevisiae (ASCA) and autoantibodies in patients with inflammatory bowel disease].
    Beltrão M; Bodas A; Azevedo F; Nunes A; Santos C; Delgado L
    Acta Med Port; 2010; 23(5):829-36. PubMed ID: 21144323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.